A Phase 2 interventional study of NBI-74788 in CAH - Congenital Adrenal Hyperplasia, sponsored by Neurocrine Biosciences. Completed at 6 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-05-03.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences — 2 open to participants now, 5 under way, 2 of them phase 3. Adrenal Hyperplasia, Congenital · Neurocrine Biosciences.
Among the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 9th registered.
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
Browse Adrenal Hyperplasia, Congenital studies →2 of the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences are open now, in 1 country. Recruiting first, the newest first:
Neurocrine Switzerland GmbH · Sites in United States
Ages 3 mo–47 mo
Neurocrine Biosciences
Ages 18–65
By country, each count listing its studies:
Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 37 across 50 interventional studies indexed under Adrenal Hyperplasia, Congenital.
Median enrollment 24 across the 16 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 in up to 30 adult female and male subjects (18 to 50 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). The study will include a sequential-cohort design with four NBI-74788 dosing regimens, with each regimen administered for 14 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NBI-74788 50 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
Drug: NBI-74788
NBI-74788 100 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
Drug: NBI-74788
NBI-74788 100 mg once daily in the evening (QPM) administered orally for 14 consecutive days.
Drug: NBI-74788
NBI-74788 100 mg twice daily (BID) administered orally for 14 consecutive days.
Drug: NBI-74788
Capsule, administered daily.
Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages
Percent changes in 17-OHP were assessed through the collection of samples from 0600 hours to 1000 hours both prior to study drug administration (i.e., at baseline) and after 14 days of study drug dosing. The 3 samples collected during this morning window at each visit were averaged and used to determine the percent change from baseline.
Time frame: Baseline and Day 14
Percent Change From Baseline to Day 14 in Androstenedione Morning Window Averages
Percent changes in androstenedione were assessed through the collection of samples from 0600 hours to 1000 hours prior to study drug administration (baseline) and after 14 days of study drug dosing. The 3 samples collected at each visit during this morning window were averaged and used to determine the change and percent change from baseline.
Time frame: Baseline and Day 14
Percent Change From Baseline to Day 14 in Adrenocorticotropic Hormone (ACTH) Morning Window Averages
Percent changes in ACTH were assessed through the collection of samples from 0600 hours to 1000 hours prior to study drug administration (baseline) and after 14 days of study drug dosing. The 3 samples collected at each visit during this morning window were averaged and used to determine the change and percent change from baseline.
Time frame: Baseline and Day 14
The study followed a sequential cohort design with four NBI-74788 dosing regimens, each administered for 14 consecutive days. There was \~2-week period to evaluate safety and tolerability data before proceeding from Cohort 1 to Cohort 2. Subjects who previously completed the study in Cohort 1 or 2 (and had no safety concerns) could reenroll into Cohorts 3 and/or 4 (in addition to new subjects); 18 unique subjects participated. First subject enrolled: 4/10/2018; Last subject completed: 4/7/2020
| Milestone | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Started | 8 | 0 | 0 | 0 |
| Completed | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Started | 0 | 7 | 0 | 0 |
| Completed | 0 | 7 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Started | 0 | 0 | 8 | 0 |
| Completed | 0 | 0 | 8 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 8 |
| Completed | 0 | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Percent changes in 17-OHP were assessed through the collection of samples from 0600 hours to 1000 hours both prior to study drug administration (i.e., at baseline) and after 14 days of study drug dosing. The 3 samples collected during this morning window at each visit were averaged and used to determine the percent change from baseline.
| Percent (%) | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages | -60 (-85 to -32) | -58 (-93 to 8) | -53 (-86 to -43) | -64 (-86 to -51) |
Percent changes in androstenedione were assessed through the collection of samples from 0600 hours to 1000 hours prior to study drug administration (baseline) and after 14 days of study drug dosing. The 3 samples collected at each visit during this morning window were averaged and used to determine the change and percent change from baseline.
| Percent (%) | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Percent Change From Baseline to Day 14 in Androstenedione Morning Window Averages | -21 (-55 to -7) | -42 (-70 to -23) | -51 (-70 to 50) | -64 (-68 to -52) |
Percent changes in ACTH were assessed through the collection of samples from 0600 hours to 1000 hours prior to study drug administration (baseline) and after 14 days of study drug dosing. The 3 samples collected at each visit during this morning window were averaged and used to determine the change and percent change from baseline.
| Percent (%) | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Percent Change From Baseline to Day 14 in Adrenocorticotropic Hormone (ACTH) Morning Window Averages | -54 (-75 to -32) | -63 (-80 to -39) | -64 (-87 to -3) | -66 (-78 to -47) |
Collected over Up to 7 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (50 mg QHS) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Cohort 2 (100 mg QHS) | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Cohort 3 (100 mg QPM) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Cohort 4 (100 mg BID) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Event | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/8 | 1/7 | 0/8 | 0/8 |
| Event | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/8 | 0/7 | 1/8 | 0/8 |
| HeadacheNervous system disorders | 3/8 | 1/7 | 0/8 | 1/8 |
| NasopharyngitisInfections and infestations | 0/8 | 0/7 | 0/8 | 2/8 |
| ContusionInjury, poisoning and procedural complications | 2/8 | 0/7 | 0/8 | 0/8 |
| DyspepsiaGastrointestinal disorders | 0/8 | 1/7 | 0/8 | 0/8 |
| Gastrointestinal painGastrointestinal disorders | 0/8 | 1/7 | 0/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/8 | 1/7 | 0/8 | 0/8 |
| Feeling abnormalGeneral disorders | 0/8 | 1/7 | 0/8 | 0/8 |
| InsomniaPsychiatric disorders | 0/8 | 1/7 | 0/8 | 1/8 |
| Hepatic enzyme increasedInvestigations | 0/8 | 1/7 | 0/8 | 0/8 |
| Age, Continuous(years) | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) | Total |
|---|---|---|---|---|---|
| Cohort 1 (50 mg QHS) | 31.1 ± 9.4 | — | — | — | 31.1 ± 9.4 |
| Cohort 2 (100 mg QHS) | — | 32.9 ± 9.7 | — | — | 32.9 ± 9.7 |
| Cohort 3 (100 mg QPM) | — | — | 30.9 ± 10.5 | — | 30.9 ± 10.5 |
| Cohort 4 (100 mg BID) | — | — | — | 28.8 ± 8.2 | 28.8 ± 8.2 |
| Sex: Female, Male(Participants) | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) | Total |
|---|---|---|---|---|---|
| Cohort 1 (50 mg QHS) — Female | 4 | — | — | — | 4 |
| Cohort 1 (50 mg QHS) — Male | 4 | — | — | — | 4 |
| Cohort 2 (100 mg QHS) — Female | — | 5 | — | — | 5 |
| Cohort 2 (100 mg QHS) — Male | — | 2 | — | — | 2 |
| Cohort 3 (100 mg QPM) — Female | — | — | 3 | — | 3 |
| Cohort 3 (100 mg QPM) — Male | — | — | 5 | — | 5 |
| Cohort 4 (100 mg BID) — Female | — | — | — | 5 | 5 |
| Cohort 4 (100 mg BID) — Male | — | — | — | 3 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) | Total |
|---|---|---|---|---|---|
| Cohort 1 (50 mg QHS) — Hispanic or Latino | 1 | — | — | — | 1 |
| Cohort 1 (50 mg QHS) — Not Hispanic or Latino | 7 | — | — | — | 7 |
| Cohort 1 (50 mg QHS) — Unknown or Not Reported | 0 | — | — | — | 0 |
| Cohort 2 (100 mg QHS) — Hispanic or Latino | — | 0 | — | — | 0 |
| Cohort 2 (100 mg QHS) — Not Hispanic or Latino | — | 7 | — | — | 7 |
| Cohort 2 (100 mg QHS) — Unknown or Not Reported | — | 0 | — | — | 0 |
| Cohort 3 (100 mg QPM) — Hispanic or Latino | — | — | 1 | — | 1 |
| Cohort 3 (100 mg QPM) — Not Hispanic or Latino | — | — | 7 | — | 7 |
| Cohort 3 (100 mg QPM) — Unknown or Not Reported | — | — | 0 | — | 0 |
| Cohort 4 (100 mg BID) — Hispanic or Latino | — | — | — | 0 | 0 |
| Cohort 4 (100 mg BID) — Not Hispanic or Latino | — | — | — | 8 | 8 |
| Cohort 4 (100 mg BID) — Unknown or Not Reported | — | — | — | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 (50 mg QHS) | Cohort 2 (100 mg QHS) | Cohort 3 (100 mg QPM) | Cohort 4 (100 mg BID) | Total |
|---|---|---|---|---|---|
| Cohort 1 (50 mg QHS) — American Indian or Alaska Native | 0 | — | — | — | 0 |
| Cohort 1 (50 mg QHS) — Asian | 1 | — | — | — | 1 |
| Cohort 1 (50 mg QHS) — Native Hawaiian or Other Pacific Islander | 0 | — | — | — | 0 |
| Cohort 1 (50 mg QHS) — Black or African American | 0 | — | — | — | 0 |
| Cohort 1 (50 mg QHS) — White | 7 | — | — | — | 7 |
| Cohort 1 (50 mg QHS) — More than one race | 0 | 0 | — | — | 0 |
| Cohort 1 (50 mg QHS) — Unknown or Not Reported | 0 | — | — | — | 0 |
| Cohort 2 (100 mg QHS) — American Indian or Alaska Native | — | 0 | — | — | 0 |
| Cohort 2 (100 mg QHS) — Asian | — | 0 | — | — | 0 |
| Cohort 2 (100 mg QHS) — Native Hawaiian or Other Pacific Islander | — | 0 | — | — | 0 |
| Cohort 2 (100 mg QHS) — Black or African American | — | 0 | — | — | 0 |
| Cohort 2 (100 mg QHS) — White | — | 7 | — | — | 7 |
| Cohort 2 (100 mg QHS) — More than one race | — | 0 | — | — | 0 |
| Cohort 2 (100 mg QHS) — Unknown or Not Reported | — | 0 | — | — | 0 |
| Cohort 3 (100 mg QPM) — American Indian or Alaska Native | — | — | 0 | — | 0 |
| Cohort 3 (100 mg QPM) — Asian | — | — | 1 | — | 1 |
| Cohort 3 (100 mg QPM) — Native Hawaiian or Other Pacific Islander | — | — | 0 | — | 0 |
| Cohort 3 (100 mg QPM) — Black or African American | — | — | 0 | — | 0 |
| Cohort 3 (100 mg QPM) — White | — | — | 7 | — | 7 |
| Cohort 3 (100 mg QPM) — More than one race | — | — | 0 | — | 0 |
| Cohort 3 (100 mg QPM) — Unknown or Not Reported | — | — | 0 | — | 0 |
| Cohort 4 (100 mg BID) — American Indian or Alaska Native | — | — | — | 0 | 0 |
| Cohort 4 (100 mg BID) — Asian | — | — | — | 0 | 0 |
| Cohort 4 (100 mg BID) — Native Hawaiian or Other Pacific Islander | — | — | — | 0 | 0 |
| Cohort 4 (100 mg BID) — Black or African American | — | — | — | 0 | 0 |
| Cohort 4 (100 mg BID) — White | — | — | — | 8 | 8 |
| Cohort 4 (100 mg BID) — More than one race | — | — | — | 0 | 0 |
| Cohort 4 (100 mg BID) — Unknown or Not Reported | — | — | — | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Apr 2020, 23 months.
Results were first posted in May 2022, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crinecerfont
Adrenal Hyperplasia, Congenital →